Results 71 to 80 of about 6,506,258 (188)
Objective: Follicular and mantle cell lymphoma are low-grade B-cell malignancies that lack good responses to chemoimmunotherapy. This study aimed to assess retrospectively clinicopathological features and to determine independent prognostic factors for ...
Guilherme Rossi Assis-Mendonça +8 more
doaj +1 more source
Recurrent mantle cell lymphoma in the uterine cervix: a case report
Background Mantle cell lymphoma is one of several subtypes of non-Hodgkin lymphoma. Cervical relapse of non-Hodgkin lymphoma is a very rare condition that has a variable and nonspecific presentation and may resemble other neoplastic or inflammatory ...
Giusi Santangelo +10 more
doaj +1 more source
Baseline immunophenotype and gene expression predict suitability for salvage nivolumab in patients with relapsed/refractory haematological malignancy. Summary Allogeneic haematopoietic stem cell transplantation (alloHSCT) relies on donor‐derived T cells to mediate the graft‐versus‐tumour (GVT) effect, but relapse may result from impaired immune ...
Trung Q. Ngo +7 more
wiley +1 more source
Discovery of novel molecular and biochemical predictors of response and outcome in diffuse large B-cell lymphoma [PDF]
PhDDiscovery of Novel Molecular and Biochemical Predictors of Response and Outcome in Diffuse Large B-cell Lymphoma Diffuse large B-cell lymphoma (DLBCL) is the commonest form of non-Hodgkin lymphoma and responds to treatment with a 5-year overall ...
Last, Kim William
core +3 more sources
Relapsed Mantle Cell Lymphoma Presenting as “Sister Mary Joseph Nodule”
The finding of umbilical metastasis has historically been called a “Sister Mary Joseph Nodule”. A few case reports of lymphoma presenting in this manner have been documented. We report a case of relapsed mantle cell lymphoma (MCL) presenting as a Sister
Jennifer E. Vaughn, Ajay K. Gopal
doaj +1 more source
Activation of the phosphatidylinositol 3-kinase/mechanistic target of rapamycin pathway plays a role in the pathogenesis of non-Hodgkin lymphoma. This multicenter, open-label phase 2 study evaluated buparlisib (BKM120), a pan-class I phosphatidylinositol
Anas Younes +11 more
doaj +1 more source
Summary Younger patients with high‐risk diffuse large B‐cell lymphoma (DLBCL) frequently have unfavourable outcomes. We conducted a prospective phase II study evaluating ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R‐CHOEP+I) in patients aged 18–60 years with DLBCL and age‐adjusted international prognostic index ≥2.
Evgenii Shumilov +19 more
wiley +1 more source
Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review
Nada Alsuhebany,1– 3 Congshan Pan,4 Eileen Holovac,5 Brian Do,6 Ali McBride7 1College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia; 2King Abdulaziz Medical City, National Guard Health Affairs ...
McBride A +4 more
core
Mantle cell lymphoma presenting with lethal atraumatic splenic rupture
Mantle cell lymphoma is characterized by t(11;14) with CCND1-IGH fusion and manifests with a spectrum of disease ranging from relatively indolent to aggressive.
Frederick Eyerer +2 more
doaj
Cutaneous lesions as presentation form of mantle cell lymphoma
Mantle cell lymphoma is a type of no-Hodgkin lymphoma that affects extranodal areas, especially, bone narrow, digestive tract and Waldeyer ring. Here we report a case of mantle cell lymphoma IV Ann Arbor stage with cutaneous lesions on nasal dorsum and ...
Nayra Merino de Paz +6 more
doaj +1 more source

